Clinically relevant subgroups in COPD and asthma

European Respiratory Review

Volumn 24, Issue 136, 2015, Pages 283-298

  Turner, Alice M ^a,b   Tamasi, Lilla ^c   Schleich, Florence ^d   Hoxha, Mehmet ^e   Horvath, Ildiko ^c   Louis, Renaud ^d   Barnes, Neil ^f  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d UNIVERSITY OF LIÈGE   (Belgium)

^e Service of Allergology and Clinical Immunology UHC Mother Teresa   (Albania)

^f GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ANTIDEPRESSANT AGENT; AZITHROMYCIN; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARBOCISTEINE; CORTICOSTEROID; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLYCOPYRRONIUM BROMIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEBRIKIZUMAB; LONG ACTING DRUG; MACROLIDE; MEPOLIZUMAB; MUCOLYTIC AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; NITRATE; OXYGEN; PROTON PUMP INHIBITOR; ROFLUMILAST; SALMETEROL; TIOTROPIUM BROMIDE; UNINDEXED DRUG;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ANXIETY; ASTHMA; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COGNITIVE THERAPY; COMORBIDITY; CONGESTIVE HEART FAILURE; DEPRESSION; DISEASE EXACERBATION; EXERCISE; GASTROESOPHAGEAL REFLUX; HUMAN; ISCHEMIC HEART DISEASE; LUNG EMPHYSEMA; LUNG RESECTION; NONINVASIVE VENTILATION; OSTEOPOROSIS; OXYGEN THERAPY; PROGNOSIS; RESPIRATORY FAILURE; REVIEW; PATHOPHYSIOLOGY; PATIENT SELECTION; PHENOTYPE; PREDICTIVE VALUE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTOR;

ASTHMA; COMORBIDITY; HUMANS; PATIENT SELECTION; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS;

EID: 84930468657     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/16000617.00009014     Document Type: Review

References (192)

1. 1 Lotvall J, Akdis CA, Bacharier LB, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 2011; 127: 355-360.
2. 2 Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010; 182: 598-604.
3. 3 Parr DG. Patient phenotyping and early disease detection in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2011; 8: 338-349.
4. 4 Wedzicha JA, Rabe KF, Martinez FJ, et al. Efficacy of roflumilast in the COPD frequent exacerbator phenotype. Chest 2013; 143: 1302-1311.
5. 5 Kerwin E, Hébert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J 2012; 40: 1106-1114.
6. 6 Wang J, Nie B, Xiong W, et al. Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis. J Clin Pharm Ther 2012; 37: 204-211.
7. 7 Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting β2-agonist in one inhaler versus long-acting β2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 9: CD006829.
8. 8 Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178: 332-338.
9. 9 Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
10. 10 Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011; 365: 689-698.
11. 11 Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011; 364: 1093-1103.
12. 12 Poole P, Black PN, Cates CJ. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 8: CD001287.
13. 13 Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long-acting bronchodilators: two randomised clinical trials. Lancet 2009; 374: 695-703.
14. 14 Rennard SI, Calverley PM, Goehring UM, et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD. Respir Res 2011; 12: 18.
15. 15 Stockley RA, Parr DG, Piitulainen E, et al. Therapeutic efficacy of α-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry. Respir Res 2010; 11: 136.
16. 16 Fishman A, Martinez F, Naunheim K, et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348: 2059-2073.
17. 17 Sciurba FC, Ernst A, Herth FJ, et al. A randomized study of endobronchial valves for advanced emphysema. N Engl J Med 2010; 363: 1233-1244.
18. 18 Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980; 93: 391-398.
19. 19 Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981; 1: 681-686.
20. 20 Budweiser S, Hitzl AP, Jôrres RA, et al. Impact of noninvasive home ventilation on long-term survival in chronic hypercapnic COPD: a prospective observational study. Int J Clin Prac 2007; 61: 1516-1522.
21. 21 Budweiser S, Jorres RA, Riedl T, et al. Predictors of survival in COPD patients with chronic hypercapnic respiratory failure receiving noninvasive home ventilation. Chest 2007; 131: 1650-1658.
22. 22 McEvoy RD, Pierce RJ, Hillman D, et al. Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial. Thorax 2009; 64: 561-566.
23. 23 Funk GC, Breyer MK, Burghuber OC, et al. Long-term non-invasive ventilation in COPD after acute-on-chronic respiratory failure. Respir Med 2011; 105: 427-434.
24. 24 Köhnlein T, Windisch W, Köhler D, et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. Lancet Respir Med 2014; 2: 698-705.
25. 25 Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J 2007; 29: 906-913.
26. 26 Kitaguchi Y, Komatsu Y, Fujimoto K, et al. Sputum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthma. Int J Chron Obstruct Pulmon Dis 2012; 7: 283-289.
27. 27 Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000; 356: 1480-1485.
28. 28 Zhou Y, Zou Y, Li X, et al. Lung function and incidence of chronic obstructive pulmonary disease after improved cooking fuels and kitchen ventilation: a 9-year prospective cohort study. PLoS Med 2014; 11: e1001621.
29. 29 Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186: 155-161.
30. 30 Sundh J, Stallberg B, Lisspers K, et al. Co-morbidity, body mass index and quality of life in COPD using the Clinical COPD Questionnaire. COPD 2011; 8: 173-181.
31. 31 Tan SL, Wood AM. Chronic obstructive pulmonary disease and co-morbidities: a review and consideration of pathophysiology. Panminerva Med 2009; 51: 81-93.
32. 32 Cavailles A, Brinchault-Rabin G, Dixmier A, et al. Comorbidities of COPD. Eur Respir Rev 2013; 22: 454-475.
33. 33 Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34: 2949-3003.
34. 34 Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128: e240-e327.
35. 35 Atlantis E, Fahey P, Cochrane B, et al. Bidirectional associations between clinically relevant depression or anxiety and chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis. Chest 2013; 144: 766-777.
36. 36 Coventry PA, Gellatly JL. Improving outcomes for COPD patients with mild-to-moderate anxiety and depression: a systematic review of cognitive behavioural therapy. Br J Health Psychol 2008; 13: 381-400.
37. 37 Coventry PA, Bower P, Keyworth C, et al. The effect of complex interventions on depression and anxiety in chronic obstructive pulmonary disease: systematic review and meta-analysis. PLoS One 2013; 8: e60532.
38. 38 Yohannes AM, Alexopoulos GS. Depression and anxiety in patients with COPD. Eur Respir Rev 2014; 23: 345-349.
39. 39 Yohannes AM, Connolly MJ, Baldwin RC. A feasibility study of antidepressant drug therapy in depressed elderly patients with chronic obstructive pulmonary disease. Int J Geriatr Psychiatry 2001; 16: 451-454.
40. 40 Romme EA, Murchison JT, Edwards LD, et al. CT-measured bone attenuation in patients with chronic obstructive pulmonary disease: relation to clinical features and outcomes. J Bone Miner Res 2013; 28: 1369-1377.
41. 41 Khosla S, Bilezikian JP, Dempster DW, et al. Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab 2012; 97: 2272-2282.
42. 42 Smith BJ, Laslett LL, Pile KD, et al. Randomized controlled trial of alendronate in airways disease and low bone mineral density. Chron Respir Dis 2004; 1: 131-137.
43. 43 Nordin BE. The effect of calcium supplementation on bone loss in 32 controlled trials in postmenopausal women. Osteoporos Int 2009; 20: 2135-2143.
44. 44 Li LS, Caughey GE, Johnston KN. The association between co-morbidities and physical performance in people with chronic obstructive pulmonary disease: a systematic review. Chron Respir Dis 2014; 11: 3-13.
45. 45 Sakae TM, Pizzichini MM, Teixeira PJ, et al. Exacerbations of COPD and symptoms of gastroesophageal reflux: a systematic review and meta-analysis. J Bras Pneumol 2013; 39: 259-271.
46. 46 Sigterman KE, van Pinxteren B, Bonis PA, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2013; 5: CD002095.
47. 47 Sasaki T, Nakayama K, Yasuda H, et al. A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients. J Am Geriatr Soc 2009; 57: 1453-1457.
48. 48 Sin DD, Man JP, Man SF. The risk of osteoporosis in Caucasian men and women with obstructive airways disease. Am J Med 2003; 114: 10-14.
49. 49 Mineo TC, Ambrogi V, Mineo D, et al. Bone mineral density improvement after lung volume reduction surgery for severe emphysema. Chest 2005; 127: 1960-1966.
50. 50 Duckers JM, Evans BA, Fraser WD, et al. Low bone mineral density in men with chronic obstructive pulmonary disease. Respir Res 2011; 12: 101.
51. 51 Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128-1138.
52. 52 Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013; 1: 199-209.
53. 53 Global Initiative for Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD. www.goldcopd.com Date last accessed: April 2014.
54. 54 Simoens S, Laekeman G, Decramer M. Preventing COPD exacerbations with macrolides: a review and budget impact analysis. Respir Med 2013; 107: 637-648.
55. 55 Izquierdo-Alonso JL, Rodriguez-Gonzalezmoro JM, de Lucas-Ramos P, et al. Prevalence and characteristics of three clinical phenotypes of chronic obstructive pulmonary disease (COPD). Respir Med 2013; 107: 724-731.
56. 56 Donaldson GC, Seemungal TA, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-852.
57. 57 Kim V, Criner GJ. Chronic bronchitis and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187: 228-237.
58. 58 Laurell CB, Eriksson S. The serum alpha-l-antitrypsin in families with hypo-alpha-L-antitrypsinemia. Clin Chim Acta 1965; 11: 395-398.
59. 59 Wood AM, Simmonds MJ, Bayley DL, et al. The TNF-α gene relates to clinical phenotype in α-1-antitrypsin deficiency. Respir Res 2008; 9: 52.
60. 60 Stockley RA, Turner AM. α-1-antitrypsin deficiency: clinical variability, assessment, and treatment. Trends Mol Med 2014; 20: 105-115.
61. 61 Herth FJ, Noppen M, Valipour A, et al. Efficacy predictors of lung volume reduction with Zephyr valves in a European cohort. Eur Respir J 2012; 39: 1334-1342.
62. 62 DeMeo DL, Hersh CP, Hoffman EA, et al. Genetic determinants of emphysema distribution in the national emphysema treatment trial. Am J Respir Crit Care Med 2007; 176: 42-48.
63. 63 Greenberg JA, Singhal S, Kaiser LR. Giant bullous lung disease: evaluation, selection, techniques, and outcomes. Chest Surg Clin N Am 2003; 13: 631-649.
64. 64 Stoller JK, Panos RJ, Krachman S, et al. Oxygen therapy for patients with COPD: current evidence and the long-term oxygen treatment trial. Chest 2010; 138: 179-187.
65. 65 O’Neill B, Mahon JM, Bradley J. Short-burst oxygen therapy in chronic obstructive pulmonary disease. Respir Med 2006; 100: 1129-1138.
66. 66 British Thoracic Society Standards of Care Committee.: Non-invasive ventilation in acute respiratory failure. Thorax. 2002; 57: 192-211.
67. 67 Dave C, Turner A, Dretzke J, et al. Protocol for a systematic review and economic evaluation of the clinical and cost-effectiveness of non-hospital-based non-invasive ventilation (NIV) in patients with stable end-stage COPD with hypercapnic respiratory failure. Syst Rev 2014; 3: 32.
68. 68 Ghebre MA, Bafadhel M, Desai D, et al. Biological clustering supports both “Dutch” and “British” hypotheses of asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol 2015; 135: 63-72.
69. 69 Brightling CE, McKenna S, Hargadon B, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 2005; 60: 193-198.
70. 70 Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2012; 186: 48-55.
71. 71 Barnes N. Old data for a new paradigm. Eur Respir J 2014; 44: Suppl. 58, p1547.
72. 72 Po JY, FitzGerald JM, Carlsten C. Respiratory disease associated with solid biomass fuel exposure in rural women and children: systematic review and meta-analysis. Thorax 2011; 66: 232-239.
73. 73 Gonzalez-Garcia M, Torres-Duque CA, Bustos A, et al. Bronchial hyperresponsiveness in women with chronic obstructive pulmonary disease related to wood smoke. Int J Chron Obstruct Pulmon Dis 2012; 7: 367-373.
74. 74 Golpe R, Sanjuan Lopez P, Cano Jimenez E, et al. Distribution of clinical phenotypes in patients with chronic obstructive pulmonary disease caused by biomass and tobacco smoke. Arch Bronconeumol 2014; 50: 318-324.
75. 75 Hu G, Zhou Y, Hong W, et al. Development and systematic oxidative stress of a rat model of chronic bronchitis and emphysema induced by biomass smoke. Exp Lung Res 2013; 39: 229-240.
76. 76 Aksu F, Capan N, Aksu K, et al. C-reactive protein levels are raised in stable chronic obstructive pulmonary disease patients independent of smoking behavior and biomass exposure. J Thorac Dis 2013; 5: 414-421.
77. 77 Camp PG, Ramirez-Venegas A, Sansores RH, et al. COPD phenotypes in biomass smoke- versus tobacco smoke-exposed Mexican women. Eur Respir J 2014; 43: 725-734.
78. 78 Ramirez-Venegas A, Sansores RH, Quintana-Carrillo RH, et al. FEV1 decline in patients with chronic obstructive pulmonary disease associated with biomass exposure. Am J Respir Crit Care Med 2014; 190: 906-1002
79. 79 Vonbank K, Ziesche R, Higenbottam TW, et al. Controlled prospective randomised trial on the effects on pulmonary haemodynamics of the ambulatory long term use of nitric oxide and oxygen in patients with severe COPD. Thorax 2003; 58: 289-293.
80. 80 Stolz D, Rasch H, Linka A, et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008; 32: 619-628.
81. 81 Valerio G, Bracciale P, Grazia D’Agostino A. Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease. Ther Adv Respir Dis 2009; 3: 15-21.
82. 82 Rao RS, Singh S, Sharma BB, et al. Sildenafil improves six-minute walk distance in chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial. Indian J Chest Dis Allied Sci 2011; 53: 81-85.
83. 83 Lederer DJ, Bartels MN, Schluger NW, et al. Sildenafil for chronic obstructive pulmonary disease: a randomized crossover trial. COPD 2012; 9: 268-275.
84. 84 Hurdman J, Condliffe R, Elliot CA, et al. Pulmonary hypertension in COPD: results from the ASPIRE registry. Eur Respir J 2013; 41: 1292-1301.
85. 85 Agusti A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012; 7: e37483.
86. 86 Miravitlles M, Marin A, Monso E, et al. Colour of sputum is a marker for bacterial colonisation in chronic obstructive pulmonary disease. Respir Res 2010; 11: 58.
87. 87 Marín A, Monsó E, Garcia-Nuñez M, et al. Variability and effects of bronchial colonisation in patients with moderate COPD. Eur Respir J 2010; 35: 295-302.
88. 88 Marin A, Garcia-Aymerich J, Sauleda J, et al. Effect of bronchial colonisation on airway and systemic inflammation in stable COPD. COPD 2012; 9: 121-130.
89. 89 Sethi S, Maloney J, Grove L, et al. Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173: 991-998.
90. 90 Patel IS, Seemungal TA, Wilks M, et al. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002; 57: 759-764.
91. 91 Miravitlles M, Marín A, Monsó E, et al. Efficacy of moxifloxacin in the treatment of bronchial colonisation in COPD. Eur Respir J 2009; 34: 1066-1071.
92. 92 Uzun S, Djamin RS, Kluytmans J, et al. Influence of macrolide maintenance therapy and bacterial colonisation on exacerbation frequency and progression of COPD (COLUMBUS): study protocol for a randomised controlled trial. Trials 2012; 13: 82.
93. 93 O’Brien C, Guest PJ, Hill SL, et al. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax 2000; 55: 635-642.
94. 94 Parr DG, Guest PG, Reynolds JH, et al. Prevalence and impact of bronchiectasis in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 2007; 176: 1215-1221.
95. 95 Martinez-Garcia MA, de la Rosa Carrillo D, Soler-Cataluna JJ, et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187: 823-831.
96. 96 Patel IS, Vlahos I, Wilkinson TM, et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 400-407.
97. 97 Ehrlich RI, Adams S, Baatjies R, et al. Chronic airflow obstruction and respiratory symptoms following tuberculosis: a review of South African studies. Int J Tuberc Lung Dis 2011; 15: 886-891.
98. 98 Bush A. COPD: a pediatric disease. COPD 2008; 5: 53-67.
99. 99 Definition and classification of chronic bronchitis for clinical and epidemiological purposes. A report to the Medical Research Council by their Committee on the Aetiology of Chronic Bronchitis. Lancet 1965; 1: 775-779.
100. 100 Holme J, Stockley JA, Stockley RA. Age related development of respiratory abnormalities in non-index α-1 antitrypsin deficient studies. Respir Med 2013; 107: 387-393.
101. 101 Costello R, Deegan P, Fitzpatrick M, et al. Reversible hypercapnia in chronic obstructive pulmonary disease: a distinct pattern of respiratory failure with a favorable prognosis. Am J Med 1997; 102: 239-244.
102. 102 Saure EW, Eagan TM, Jensen RL, et al. Explained variance for blood gases in a population with COPD. Clin Respir J 2012; 6: 72-80.
103. 103 Andersen KH, Iversen M, Kjaergaard J, et al. Prevalence, predictors, and survival in pulmonary hypertension related to end-stage chronic obstructive pulmonary disease. J Heart Lung Transplant 2012; 31: 373-380.
104. 104 Hurdman J, Condliffe R, Elliot CA, et al. Pulmonary hypertension in COPD: results from the ASPIRE registry. Eur Respir J 2013; 41:1292-1301.
105. 105 Hanaoka M, Ideura G, Ito M, et al. Pulmonary haemodynamic changes in patients with severe COPD. Respirology 2008; 13: 919-922.
106. 106 Bonnet S, Savineau JP, Barillot W, et al. Role of Ca2+-sensitive K+ channels in the remission phase of pulmonary hypertension in chronic obstructive pulmonary diseases. Cardiovasc Res 2003; 60: 326-336.
107. 107 Wood AM, Bharadwa P, Bayley D, et al. Bacterial colonisation in alpha-1 antitrypsin deficiency. Eur Respir J 2008; 32: Suppl., 52, E4496.
108. 108 Murphy TF, Brauer AL, Grant BJ, et al. Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease and immune response. Am J Respir Crit Care Med 2005; 172: 195-199.
109. 109 Murphy TF, Brauer AL, Eschberger K, et al. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 853-860.
110. 110 Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012; 18: 716-725.
111. 111 Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008; 372: 1107-1119.
112. 112 Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380: 651-659.
113. 113 Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365: 1088-1098.
114. 114 Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343-373.
115. 115 Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360: 1715-1721.
116. 116 Piacentini GL, Peroni DG, Bodini A, et al. Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report. Allergy Asthma Proc 2007; 28: 194-198.
117. 117 Brusselle GG, Vanderstichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax 2013; 68: 322-329.
118. 118 Pasqualotto AC, Powell G, Niven R, et al. The effects of antifungal therapy on severe asthma with fungal sensitization and allergic bronchopulmonary aspergillosis. Respirology 2009; 14: 1121-1127.
119. 119 Denning DW, O’Driscoll BR, Powell G, et al. Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: the Fungal Asthma Sensitization Trial (FAST) study. Am J Respir Crit Care Med 2009; 179: 11-18.
120. 120 Cohen P, Pagnoux C, Mahr A, et al. Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum 2007; 57: 686-693.
121. 121 Cartin-Ceba R, Keogh KA, Specks U, et al. Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. Nephrol Dial Transplant 2011; 26: 2865-2871.
122. 122 Koh MS, Tee A, Lasserson TJ, et al. Inhaled corticosteroids compared to placebo for prevention of exercise induced bronchoconstriction. Cochrane Database Syst Rev 2007; 3: CD002739.
123. 123 Micheletto C, Tognella S, Visconti M, et al. Montelukast 10 mg improves nasal function and nasal response to aspirin in ASA-sensitive asthmatics: a controlled study vs placebo. Allergy 2004; 59: 289-294.
124. 124 Vandenplas O, Dressel H, Nowak D, et al. What is the optimal management option for occupational asthma? Eur Respir Rev 2012; 21: 97-104.
125. 125 Jia G, Erickson RW, Choy DF, et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol 2012; 130: 647-654.
126. 126 Suh DI, Lee JK, Kim CK, et al. Bronchial hyperresponsiveness to methacholine and adenosine 5′-monophosphate, and the presence and degree of atopy in young children with asthma. Clin Exp Allergy 2011; 41: 338-345.
127. 127 Green RH, Brightling CE, Woltmann G, et al. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002; 57: 875-879.
128. 128 Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178: 218-224.
129. 129 Moffatt MF, Gut IG, Demenais F, et al. A large-scale, consortium-based genomewide association study of asthma. N Engl J Med 2010; 363: 1211-1221.
130. 130 Wan YI, Shrine NR, Soler Artigas M, et al. Genome-wide association study to identify genetic determinants of severe asthma. Thorax 2012; 67: 762-768.
131. 131 Simpson JL, Scott R, Boyle MJ, et al. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology 2006; 11: 54-61.
132. 132 Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009; 180: 388-395.
133. 133 Gray L, Peat JK, Belousova E, et al. Family patterns of asthma, atopy and airway hyperresponsiveness: an epidemiological study. Clin Exp Allergy 2000; 30: 393-399.
134. 134 MacDonald C, Sternberg A, Hunter PR. A systematic review and meta-analysis of interventions used to reduce exposure to house dust and their effect on the development and severity of asthma. Environ Health Perspect 2007; 115: 1691-1695.
135. 135 Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 2011; 139: 28-35.
136. 136 Eisner MD, Zazzali JL, Miller MK, et al. Longitudinal changes in asthma control with omalizumab: 2-year interim data from the EXCELS Study. J Asthma 2012; 49: 642-648.
137. 137 Pauls JD, Simon RA, Daffern PJ, et al. Lack of effect of the 5-lipoxygenase inhibitor zileuton in blocking oral aspirin challenges in aspirin-sensitive asthmatics. Ann Allergy Asthma Immunol 2000; 85: 40-45.
138. 138 Francis HC, Prys-Picard CO, Fishwick D, et al. Defining and investigating occupational asthma: a consensus approach. Occup Environ Med 2007; 64: 361-365.
139. 139 Lemiere C, D’Alpaos V, Chaboillez S, et al. Investigation of occupational asthma: sputum cell counts or exhaled nitric oxide? Chest 2010; 137: 617-622.
140. 140 Moore VC, Anees W, Jaakkola MS, et al. Two variants of occupational asthma separable by exhaled breath nitric oxide level. Respir Med 2010;104: 873-879.
141. 141 Anees W, Moore VC, Burge PS. FEV1 decline in occupational asthma. Thorax 2006; 61: 751-755.
142. 142 Maurya V, Gugnani HC, Sarma PU, et al. Sensitization to Aspergillus antigens and occurrence of allergic bronchopulmonary aspergillosis in patients with asthma. Chest 2005; 127: 1252-1259.
143. 143 Chauhan B, Santiago L, Kirschmann DA, et al. The association of HLA-DR alleles and T cell activation with allergic bronchopulmonary aspergillosis. J Immunol 1997; 159: 4072-4076.
144. 144 Carvalho A, Pasqualotto AC, Pitzurra L, et al. Polymorphisms in toll-like receptor genes and susceptibility to pulmonary aspergillosis. J Infect Dis 2008; 197: 618-621.
145. 145 Pagnoux C, Guilpain P, Guillevin L. Churg-Strauss syndrome. Curr Opin Rheumatol 2007; 19: 25-32.
146. 146 Comarmond C, Pagnoux C, Khellaf M, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 2013; 65: 270-281.
147. 147 Langdeau JB, Turcotte H, Bowie DM, et al. Airway hyperresponsiveness in elite athletes. Am J Respir Crit Care Med 2000; 161: 1479-1484.
148. 148 Ali Z, Norsk P, Ulrik CS. Mechanisms and management of exercise-induced asthma in elite athletes. J Asthma 2012; 49: 480-486.
149. 149 Philip G, Villaran C, Pearlman DS, et al. Protection against exercise-induced bronchoconstriction two hours after a single oral dose of montelukast. J Asthma 2007; 44: 213-217.
150. 150 Duong M, Amin R, Baatjes AJ, et al. The effect of montelukast, budesonide alone, and in combination on exercise-induced bronchoconstriction. J Allergy Clin Immunol 2012; 130: 535-539.
151. 151 Lemiere C, Ernst P, Olivenstein R, et al. Airway inflammation assessed by invasive and noninvasive means in severe asthma: eosinophilic and noneosinophilic phenotypes. J Allergy Clin Immunol 2006; 118: 1033-1039.
152. 152 Zhang N, Truong-Tran QA, Tancowny B, et al. Glucocorticoids enhance or spare innate immunity: effects in airway epithelium are mediated by CCAAT/enhancer binding proteins. J Immunol 2007; 179: 578-589.
153. 153 Bhavsar P, Hew M, Khorasani N, et al. Relative corticosteroid insensitivity of alveolar macrophages in severe asthma compared with non-severe asthma. Thorax 2008; 63: 784-790.
154. 154 Simpson JL, Grissell TV, Douwes J, et al. Innate immune activation in neutrophilic asthma and bronchiectasis. Thorax 2007; 62: 211-218.
155. 155 Busacker A, Newell JD Jr., Keefe T, et al. A multivariate analysis of risk factors for the air-trapping asthmatic phenotype as measured by quantitative CT analysis. Chest 2009; 135: 48-56.
156. 156 Cowan DC, Cowan JO, Palmay R, et al. Effects of steroid therapy on inflammatory cell subtypes in asthma. Thorax 2010; 65: 384-390.
157. 157 Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010; 181: 315-323.
158. 158 Mauad T, Silva LF, Santos MA, et al. Abnormal alveolar attachments with decreased elastic fiber content in distal lung in fatal asthma. Am J Respir Crit Care Med 2004; 170: 857-862.
159. 159 Sutherland ER, Goleva E, King TS, et al. Cluster analysis of obesity and asthma phenotypes. PLoS One 2012; 7: e36631.
160. 160 Juel CT, Ali Z, Nilas L, et al. Asthma and obesity: does weight loss improve asthma control? a systematic review. J Asthma Allergy 2012; 5: 21-26.
161. 161 Havemann BD, Henderson CA, El-Serag HB. The association between gastro-oesophageal reflux disease and asthma: a systematic review. Gut 2007; 56: 1654-1664.
162. 162 Scarupa MD, Mori N, Canning BJ. Gastroesophageal reflux disease in children with asthma: treatment implications. Paediatr Drugs 2005; 7: 177-186.
163. 163 Kiljander TO, Junghard O, Beckman O, et al. Effect of esomeprazole 40 mg once or twice daily on asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2010; 181: 1042-1048.
164. 164 Gibson PG, Henry RL, Coughlan JL. Gastro-oesophageal reflux treatment for asthma in adults and children. Cochrane Database Syst Rev 2003; 2: CD001496.
165. 165 Rao CK, Moore CG, Bleecker E, et al. Characteristics of perimenstrual asthma (PMA) and its relation to asthma severity and control: data from the Severe Asthma Research Program. Chest 2013; 143: 984-995.
166. 166 Farha S, Asosingh K, Laskowski D, et al. Effects of the menstrual cycle on lung function variables in women with asthma. Am J Respir Crit Care Med 2009; 180: 304-310.
167. 167 Thornton J, Lewis J, Lebrun CM, et al. Clinical characteristics of women with menstrual-linked asthma. Respir Med 2012; 106: 1236-1243.
168. 168 Abayaratne D, Kurukulaaratchy RJ. Recognising the risk of aspirin-sensitive respiratory disease in a patient with asthma who has previously tolerated aspirin. Prim Care Respir J 2011; 20: 214-217.
169. 169 Makowska JS, Grzegorczyk J, Bienkiewicz B, et al. Systemic responses after bronchial aspirin challenge in sensitive patients with asthma. J Allergy Clin Immunol 2008; 121: 348-354.
170. 170 Mastalerz L, Sanak M, Kumik J, et al. Exhaled eicosanoids following bronchial aspirin challenge in asthma patients with and without aspirin hypersensitivity: the pilot study. J Allergy 2012; 2012: 696792.
171. 171 Stelmach I, Sobocinska A, Majak P, et al. Comparison of the long-term efficacy of 3- and 5-year house dust mite allergen immunotherapy. Ann Allergy Asthma Immunol 2012; 109: 274-278.
172. 172 Ho MH, Wong WH, Heine RG, et al. Early clinical predictors of remission of peanut allergy in children. J Allergy Clin Immunol 2008; 121: 731-736.
173. 173 Burgess JA, Matheson MC, Gurrin LC, et al. Factors influencing asthma remission: a longitudinal study from childhood to middle age. Thorax 2011; 66: 508-513.
174. 174 Aslund N, Thomsen SF, Molgaard E, et al. Changes in skin test reactivity among adults with atopic disease: a 3-year prospective study. Ann Allergy Asthma Immunol 2008; 101: 524-528.
175. 175 McGrath KW, Icitovic N, Boushey HA, et al. A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med 2012; 185: 612-619.
176. 176 Fleming L, Tsartsali L, Wilson N, et al. Sputum inflammatory phenotypes are not stable in children with asthma. Thorax 2012; 67: 675-681.
177. 177 Kato T, Takeda Y, Nakada T, et al. Inhibition by dexamethasone of human neutrophil apoptosis in vitro. Nat Immun 1995; 14: 198-208.
178. 178 Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax 2009; 64: 728-735.
179. 179 Soler-Cataluna JJ, Cosio B, Izquierdo JL, et al. Consensus document on the overlap phenotype COPD-asthma in COPD. Arch Bronconeumol 2012; 48: 331-337.
180. 180 Soriano JB, Davis KJ, Coleman B, et al. The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. Chest 2003; 124: 474-481.
181. 181 Hardin M, Silverman EK, Barr RG, et al. The clinical features of the overlap between COPD and asthma. Respir Res 2011; 12: 127.
182. 182 Decramer M, Celli B, Kesten S, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374: 1171-1178.
183. 183 Hospers JJ, Postma DS, Rijcken B, et al. Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. Lancet 2000; 356: 1313-1317.
184. 184 Shaya FT, Dongyi D, Akazawa MO, et al. Burden of concomitant asthma and COPD in a Medicaid population. Chest 2008; 134: 14-19.
185. 185 Papi A, Romagnoli M, Baraldo S, et al. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 162: 1773-1777.
186. 186 Bumbacea D, Campbell D, Nguyen L, et al. Parameters associated with persistent airflow obstruction in chronic severe asthma. Eur Respir J 2004; 24: 122-128.
187. 187 Blanc PD. Occupation and COPD: a brief review. J Asthma 2012; 49: 2-4.
188. 188 Mir E, Shah A. Allergic bronchopulmonary aspergillosis in a patient with chronic obstructive pulmonary disease. Prim Care Respir J 2012; 21: 111-114.
189. 189 Saetta M, Di Stefano A, Maestrelli P, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994; 150: 1646-1652.
190. 190 Fens N, Zwinderman AH, van der Schee MP, et al. Exhaled breath profiling enables discrimination of chronic obstructive pulmonary disease and asthma. Am J Respir Crit Care Med 2009; 180: 1076-1082.
191. 191 ten Brinke A, Sterk PJ, Masclee AA, et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J 2005; 26: 812-818.
192. 192 Hahn DL, Plane MB, Mahdi OS, et al. Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma. PLoS Clin Trials 2006; 1: e11.